AlloVir (ALVR) Revenue & Revenue Breakdown
AlloVir Revenue Highlights
Main Segment (Y)
Grant
Main Geography (Y)
Grant
AlloVir Revenue by Period
AlloVir Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | -100.00% |
2019-12-31 | $165.00K | -85.46% |
2018-12-31 | $1.14M | - |
AlloVir Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $8.38M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | -100.00% |
2019-03-31 | $165.00K | - |
AlloVir Revenue Breakdown
AlloVir Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 20 |
---|---|
Grant | $900.00K |
Quarterly Revenue by Product
Product/Service | Dec 20 | Sep 20 | Jun 20 |
---|---|---|---|
Grant | $200.00K | $400.00K | $300.00K |
AlloVir Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 20 |
---|---|
Grant | $900.00K |
Quarterly Revenue by Country
Country | Dec 20 | Sep 20 | Jun 20 |
---|---|---|---|
Grant | $200.00K | $400.00K | $300.00K |
AlloVir Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
MRUS | Merus | $43.95M | $11.77M |
AGIO | Agios Pharmaceuticals | $26.82M | $8.96M |
ADAG | Adagene | $18.11M | $833.34K |
ANAB | AnaptysBio | $17.16M | $10.97M |
STOK | Stoke Therapeutics | $8.78M | $4.22M |
KRON | Kronos Bio | $6.29M | $2.69M |
CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
INBX | Inhibrx Biosciences | $1.80M | - |
FIXX | Q32 Bio | $1.16M | - |
BCEL | Atreca | $770.00K | $80.00K |
LYEL | Lyell Immunopharma | $130.00K | $3.00K |
ANEB | Anebulo Pharmaceuticals | - | - |
CGEM | Cullinan Oncology | - | - |
ALVR | AlloVir | - | - |
BDTX | Black Diamond Therapeutics | - | - |
ANTX | AN2 Therapeutics | - | - |
AVTE | Aerovate Therapeutics | - | - |
ACRV | Acrivon Therapeutics | - | - |
MLYS | Mineralys Therapeutics | - | - |
FDMT | 4D Molecular Therapeutics | - | - |
ALVR Revenue FAQ
What is AlloVir’s yearly revenue?
AlloVir's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. ALVR's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is AlloVir’s quarterly revenue?
AlloVir's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). ALVR's quarterly revenue for Q4 2023 was $8.38M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is AlloVir’s revenue growth rate?
AlloVir's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was -100.00%.
What are AlloVir’s revenue streams?
AlloVir's revenue streams in c 20 are Grant
What is AlloVir’s main source of revenue?
For the fiscal year ending Dec 20, the largest source of revenue of AlloVir was Grant. This segment made a revenue of $900K, representing 100.00% of the company's total revenue.